Purpose: To report a case of retinal vasculitis after intravitreal faricimab-svoa injection. Methods: A case and its management were reviewed. Results: A 77-year-old woman presented with a painless decrease in visual acuity (VA) to counting fingers after receiving an intravitreal faricimab-svoa injection for neovascular age-related macular degeneration. An examination showed an anterior chamber reaction without hypopyon. Vitritis was present with numerous scattered retinal hemorrhages. Fluorescein angiography showed delayed filling with extensive vascular leakage consistent with nonocclusive vasculitis. The patient was immediately treated with intravenous steroids, resulting in rapid improvement and recovery of her 20/40 baseline VA. The vasculitis resolved without occlusion. Conclusions: Faricimab-svoa can be associated with significant vasculitis. Prompt treatment with intravenous steroids can be beneficial in the recovery of sight.
LamLAMehtaSLadEMEmersonGGMichael JumperJAwhCC.Intravitreal injection therapy: current techniques and supplemental services. J Vitreoretin Dis. 2021;5(5):438-447 doi:10.1177/24741264211028441
2.
AndersonWJda CruzNFSLimaLHEmersonGGRodriguesEBMeloGB.Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. Int J Retina Vitreous. 2021;7(1):37-49. doi:10.1186/S40942-021-00307-7
3.
PakravanPPatelVLaiJ, et al. Intraocular inflammation incidence after intravitreal brolucizumab injection for exudative age-related macular degeneration. Retina. 2023;43(10):1717-1722. doi:10.1097/IAE.0000000000003862
4.
WitkinAJJaffeGJSrivastavaSKDavisJLKimJE.Retinal vasculitis after intravitreal pegcetacoplan: report from the ASRS research and safety in therapeutics (ReST) committee. J Vitreoretin Dis. 2023;8(1):9-20. doi:10.1177/24741264231220224
5.
NicolòMFerro DesideriLVaggeATraversoCE.Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021;30(3):193-200. doi:10.1080/13543784.2021.1879791
6.
LarsenHOGrauslundJVergmannAS.Efficacy, durability and safety of faricimab in neovascular age-related macular degeneration and diabetic macular oedema: lessons learned from registration trials. Ophthalmol Ther. 2023;12(5):2253. doi:10.1007/S40123-023-00753-6
7.
KhananiAMAzizAAKhanH, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results. Eye. 2023;37(17):3574-3581. doi:10.1038/s41433-023-02553-5
8.
HeierJSKhananiAMQuezada RuizC, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. The Lancet. 2022;399(10326):729-740. doi:10.1016/S0140-6736(22)00010-1
9.
MomenaeiBWangKKazanAS, et al. Rates of ocular adverse events following intravitreal faricimab injections. Ophthalmol Retina. Published online December 7, 2023. doi:10.1016/J.ORET.2023.12.001
10.
GreenbergEDedekerCOlsonHJMontezumaRS.Postoperative cataract endophthalmitis masquerading as hemorrhagic occlusive retinal vasculitis (HORV): A case report. Ocul Immunol Inflamm. 2021;29(4):758-761. doi:10.1080/09273948.2019.1634216
11.
ConradyCDFeistmannJARollerABBoldtHCShakoorA.Hemorrhagic vasculitis and retinopathy heralding as an early sign of bacterial endophthalmitis after intravitreal injection. Retin Cases Brief Rep. 2019;13(4):329-332. doi:10.1097/ICB.0000000000000601
12.
BaumalCRBodaghiBSingerM, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmol Retina. 2021;5(6):519-527. doi:10.1016/j.oret.2020.09.020
13.
AldhefeeryNAlhadhoodNAlkadiA.Bilateral retinal vasculitis as initial presentation of systemic lupus erythematosus with secondary antiphospholipid syndrome. Am J Case Rep. 2023;24:e942085. doi:10.12659/AJCR.942085
14.
KhananiAMZarbinMABarakatMR, et al. Safety outcomes of brolucizumab in neovascular age-related macular degeneration: Results from the IRIS registry and komodo healthcare map. JAMA Ophthalmol. 2022;140(1):20-28. doi:10.1001/jamaophthalmol.2021.4585
15.
Cruz-PimentelMWuL.Complement inhibitors for advanced dry age-related macular degeneration (geographic atrophy): Some light at the end of the tunnel?J Clin Med. 2023;12(15):1531. doi:10.3390/jcm12155131
16.
WitkinAJHahnPMurrayTG, et al. Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis. J Vitreoretin Dis. 2021;5(4):326-332. doi:10.1177/2474126420975303
